Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 1/20 | 0.51 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | FLT1 | P17948 | 1/20 | 0.34 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.34 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.34 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.34 |
| ▸ | FLT4 | P35916 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4605648 | 1.00 | ERBB2 (0.51) | ERBB2MINK1FGFR1FLT1FGFR2 | |
| SCHEMBL4606263 | 0.89 | ERBB2 (0.61) | ERBB2MINK1MAPT | |
| SCHEMBL4606257 | 0.89 | ERBB2 (0.61) | ERBB2MINK1MAPT | |
| SCHEMBL4606786 | 0.89 | ERBB2 (0.43) | ERBB2MINK1FGFR1FLT1FGFR2 | |
| SCHEMBL4606790 | 0.89 | ERBB2 (0.43) | ERBB2MINK1FGFR1FLT1FGFR2 | |
| SCHEMBL5385106 | 0.88 | ERBB2 (0.66) | ERBB2MINK1FGFR1FLT1FGFR2 | |
| SCHEMBL5385109 | 0.88 | ERBB2 (0.66) | ERBB2MINK1FGFR1FLT1FGFR2 | |
| SCHEMBL5561683 | 0.88 | ERBB2 (0.52) | ERBB2MINK1FGFR1FLT1FGFR2 | |
| SCHEMBL5561502 | 0.88 | ERBB2 (0.52) | ERBB2MINK1FGFR1FLT1FGFR2 | |
| SCHEMBL4606806 | 0.87 | ERBB2 (0.61) | ERBB2MINK1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1761525-B1 | THIOETHER DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | HOFFMANN LA ROCHE (CH) | 2008-07-23 | — | — | EP | claimed |
| US-7005526-B2 | Thioether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-02-28 | — | — | US | claimed |
| US-20050267179-A1 | NOVEL THIOETHER DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-01 | — | — | US | claimed |
| EP-1761525-B1 | THIOETHER DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | HOFFMANN LA ROCHE (CH) | 2008-07-23 | — | — | EP | disclosed |
| EP-1761525-A1 | THIOETHER DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-03-14 | — | — | EP | disclosed |
| US-7005526-B2 | Thioether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-02-28 | — | — | US | disclosed |
| WO-2005116019-A1 | THIOETHER DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-08 | — | — | WO | disclosed |
| US-20050267179-A1 | NOVEL THIOETHER DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267179-A1 | NOVEL THIOETHER DERIVATIVES | TPMT, TST, SULT1E1 | ERBB2 581/4885MINK1 2814/4885FGFR1 2380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.